特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

経口抗糖尿病薬の世界市場 - スルホニル尿素、メグリチニド、ビグアニド、α-グルコシダーゼ阻害剤

Oral Antidiabetic Drugs Market by Drugs Class Category (Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors) for Type 2 Diabetes mellitus - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022

発行 Zion Market Research 商品コード 522830
出版日 ページ情報 英文 110 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.17円で換算しております。
経口抗糖尿病薬の世界市場 - スルホニル尿素、メグリチニド、ビグアニド、α-グルコシダーゼ阻害剤 Oral Antidiabetic Drugs Market by Drugs Class Category (Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors) for Type 2 Diabetes mellitus - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022
出版日: 2017年01月06日 ページ情報: 英文 110 Pages
概要

当レポートでは、世界の糖尿病向け経口薬の市場の将来展望について分析し、世界全体の市場動向見通し (通算7年間分) や、薬剤クラス別・地域別の詳細動向、市場の基本構造および主な市場促進・抑制要因、市場競争環境 (市場シェア構造、主な資本取引動向ほか)、主要企業の概略・業績・戦略構想などを調査しております。

第1章 イントロダクション

第2章 エグゼクティブ・サマリー

  • 世界の経口抗糖尿病薬市場:動向予測 (金額ベース、通算7年間分)
  • 世界の経口抗糖尿病薬市場:概況

第3章 経口抗糖尿病薬市場のダイナミクス

  • イントロダクション
  • バリューチェーン分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • ポーターのファイブフォース分析
  • 市場求心力の分析

第4章 世界の経口抗糖尿病薬市場:競争環境

  • 市場シェア分析 (最新値)
  • 戦略展開状況
    • 企業合併・買収 (M&A)
    • 新製品の上市
    • 協定、事業提携、事業協力、合弁事業
    • 研究開発 (R&D)、他地域進出
  • 製品ポートフォリオ

第5章 世界の経口抗糖尿病薬市場:薬剤クラス別の分析

  • 市場概要:薬剤クラス別
    • 市場収益額シェア:薬剤クラス別 (最新値・予測値)
  • スルホニル尿素
    • 世界のスルホニル尿素市場:最新値・予測値 (金額ベース)
    • グリメピリド
    • グリクラジド
    • グリブリド
    • その他
  • メグリチニド
    • 世界のメグリチニド市場:最新値・予測値 (金額ベース)
    • レパグリニド
    • ナテグリニド
  • ビグアニド
    • 世界のビグアニド市場:最新値・予測値 (金額ベース)
    • メトホルミン
    • その他
  • α-グルコシダーゼ阻害剤
    • 世界のα-グルコシダーゼ阻害剤市場:最新値・予測値 (金額ベース)
    • アカルボース
    • ボグリボース
    • その他

第7章 世界の経口抗糖尿病薬市場:地域別の分析

  • 市場概要:地域別
  • 北米市場 (米国、カナダ)
  • 欧州市場 (ドイツ、フランス、英国)
  • アジア太平洋地域市場 (中国、日本、インド)
  • ラテンアメリカ市場 (ブラジル)
  • 中東・アフリカ市場

第7章 企業プロファイル

目次

The report covers forecast and analysis for the oral antidiabetic drugs market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based on revenue (USD billion). The study includes drivers and restraints of the oral antidiabetic drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oral antidiabetic drugs market on a global level.

In order to give the users a comprehensive view of the Oral antidiabetic drugs market, we have included a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter's five forces model for the oral antidiabetic drugs market has also been included. The study encompasses a market attractiveness analysis, wherein the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view on the oral antidiabetic drugs market by segmenting the market based on drugs class and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2022. The drugs class segmentation includes sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. The meglitinides class is further segmented into repaglinide and nateglinide. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further sub-segmented into U.S., Canada, China, Japan, and Brazil.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global oral antidiabetic drugs market include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer.

This report segments the global oral antidiabetic drugs Market as follows:

Global Oral Antidiabetic Drugs Market: Drugs Class Analysis

  • Sulfonylureas
    • Glimepiride
    • Gliclazide
    • Glyburide
    • Others
  • Meglitinides
    • Repaglinide
    • Nateglinide
  • Biguanides
    • Metformin
    • Others
  • Alpha-glucosidase inhibitors
    • Acarbose
    • Voglibose
    • Others
  • Others

Global Oral Antidiabetic Drugs Market: Regional Segment Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
  • Middle East and Africa

Table of Contents

Chapter 1. Introduction

  • 1.1. Report Description And Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

Chapter 2. Executive Summary

  • 2.1. Global Oral Anti-Diabetic Market, 2016 - 2022 (USD Billion)
  • 2.2. Global Oral Anti-Diabetic Market: Snapshot

Chapter 3. Oral Anti-Diabetic - Market Dynamics

  • 3.1. Introduction
  • 3.2. Value Chain Analysis
  • 3.3. Market Drivers
    • 3.3.1. Global Oral Anti-Diabetic Market Drivers: Impact Analysis
    • 3.3.2. Rising Prevalence Of Diabetes Mellitus
    • 3.3.3. Increase In Obesity
  • 3.4. Market Restraints
    • 3.4.1. Global Oral Anti-Diabetic Market Restraints: Impact Analysis
    • 3.4.2. High Cost of Drugs
  • 3.5. Opportunities
    • 3.5.1. Market Strength
  • 3.6. Porter's Five Forces Analysis
    • 3.6.1. Bargaining Power Of Suppliers
    • 3.6.2. Bargaining Power Of Buyers
    • 3.6.3. Threat From New Entrants
    • 3.6.4. Threat From New Substitutes
    • 3.6.5. Degree Of Competition
  • 3.7. Market Attractiveness Analysis
    • 3.7.1. Market Attractiveness Analysis, By Drug Class Segment
    • 3.7.2. Market Attractiveness Analysis, By Regional Segment

Chapter 4. Global Oral Anti-Diabetic Market - Competitive Landscape

  • 4.1. Company Market Share, 2016 (Subject To Data Availability)
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions & Mergers
    • 4.2.2. New Type Launch
    • 4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
    • 4.2.4. Research And Development, Regional Expansion
  • 4.3. Type Portfolio

Chapter 5. Global Oral Anti-Diabetic Market - Drug Class Analysis

  • 5.1. Global Oral Anti-Diabetic Market: Drug Class Segment Overview
    • 5.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Drug Class, 2016 And 2022
  • 5.2. Sulfonylureas
    • 5.2.1. Global Sulfonylureas Market, 2016 - 2022 (USD Billion)
    • 5.2.2. Glimepiride
      • 5.2.2.1. Glimepiride Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.2.3. Gliclazide
      • 5.2.3.1. Gliclazide Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.2.4. Glyburide
      • 5.2.4.1. Glyburide Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.2.5. Others
      • 5.2.5.1. Others Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
  • 5.3. Meglitinides
    • 5.3.1. Global Meglitinides Market, 2016 - 2022 (USD Billion)
    • 5.3.2. Repaglinide
      • 5.3.2.1. Repaglinide Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.3.3. Nateglinide
      • 5.3.3.1. Nateglinide Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
  • 5.4. Biguanides
    • 5.4.1. Global Biguanides Market, 2016 - 2022 (USD Billion)
    • 5.4.2. Metformin
      • 5.4.2.1. Metformin Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.4.3. Others
      • 5.4.3.1. Others Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
  • 5.5. Alpha-glucosidase inhibitors
    • 5.5.1. Global Alpha-glucosidase inhibitors Market, 2016 - 2022 (USD Billion)
    • 5.5.2. Acarbose
      • 5.5.2.1. Acarbose Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.5.3. Voglibose
      • 5.5.3.1. Voglibose Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
    • 5.5.4. Others
      • 5.5.4.1. Others Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)

Chapter 6. Global Oral Anti-Diabetic Market - Regional Segment Analysis

  • 6.1. Global Oral Anti-Diabetic Market: Regional Overview
    • 6.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Region, 2016 And 2022
  • 6.2. North America
    • 6.2.1. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022, (USD Billion)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
  • 6.3. Europe
    • 6.3.1. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.3.2. Germany
      • 6.3.2.1. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022, (USD Billion)
    • 6.3.3. France
      • 6.3.3.1. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022, (USD Billion)
    • 6.3.4. U.K.
      • 6.3.4.1. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.4.2. China
      • 6.4.2.1. China Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.4.4. India
      • 6.4.4.1. India Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
  • 6.5. Latin America
    • 6.5.1. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)
  • 6.6. Middle East And Africa
    • 6.6.1. Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022 (USD Billion)

Chapter 7. Company Profile

  • 7.1. Abbott Laboratories
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Portfolio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. Biocon, Ltd
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Portfolio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. Eli Lilly and Company
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Developments
  • 7.4. Sun Pharma Industries, Ltd.
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Portfolio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Developments
  • 7.5. Novo Nordisk A/S
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Portfolio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Developments
  • 7.6. Pfizer
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Portfolio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Developments
  • 7.7. Sanofi
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Portfolio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Developments
  • 7.8. Novartis
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Product Portfolio
    • 7.8.4. Business Strategy
    • 7.8.5. Recent Developments
  • 7.9. Merck Group
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Product Portfolio
    • 7.9.4. Business Strategy
    • 7.9.5. Recent Development

List of Figures

  • 1. Market Research Process
  • 2. Market Research Methodology
  • 3. Global Oral Anti-Diabetic Market Revenue, 2016 - 2022 (USD Billion)
  • 4. Porter's Five Forces Analysis
  • 5. Oral Anti-Diabetic: Market Attractiveness Analysis, By Drug Class Segment
  • 6. Oral Anti-Diabetic: Market Attractiveness Analysis, By Regional Segment
  • 7. Company Market Share Analysis, 2016 And 2022
  • 8. Global Oral Anti-Diabetic Market Revenue Share By Drug Class, 2016 And 2022
  • 9. Sulfonylureas Market, 2016 - 2022, (USD Billion)
  • 10. Glimepiride Market, 2016 - 2022, (USD Billion)
  • 11. Gliclazide Market, 2016 - 2022, (USD Billion)
  • 12. Glyburide Market, 2016 - 2022, (USD Billion)
  • 13. Others sulphonylureas Market, 2016 - 2022, (USD Billion)
  • 14. Meglitinides Market, 2016 - 2022, (USD Billion)
  • 15. Repaglinide Market, 2016 - 2022, (USD Billion)
  • 16. Nateglinide Market, 2016 - 2022, (USD Billion)
  • 17. Biguanides Market, 2016 - 2022, (USD Billion)
  • 18. Metformin Market, 2016 - 2022, (USD Billion)
  • 19. Others Market, 2016 - 2022, (USD Billion)
  • 20. Alpha-glucosidase inhibitors Market, 2016 - 2022, (USD Billion)
  • 21. Acarbose Market, 2016 - 2022, (USD Billion)
  • 22. Voglibose Market, 2016 - 2022, (USD Billion)
  • 23. Others Market, 2016 - 2022, (USD Billion)
  • 24. Global Oral Anti-Diabetic Market Share, By Region, 2016 - 2022
  • 25. North America Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 26. U.S. Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 27. Canada Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 28. Europe Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 29. Asia-Pacific Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 30. China Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 31. Japan Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 32. India Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 33. Latin America Oral Anti-Diabetic Market, 2016-2022, (USD Billion)
  • 34. Brazil Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)
  • 35. Middle East & Africa Oral Anti-Diabetic Market, 2016 - 2022, (USD Billion)

List of Tables

  • 1. Oral Anti-Diabetic Market: Market Snapshot
  • 2. Drivers Of Global Oral Anti-Diabetic Market: Impact Analysis
  • 3. Restraints Of Global Oral Anti-Diabetic Market: Impact Analysis
  • 4. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 5. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 6. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 7. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 8. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 9. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 10. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 - 2022(USD Billion)
  • 11. Asia-Pacific Oral Anti-Diabetic Market Revenue, By Drug Class 2016 - 2022(USD Billion)
  • 12. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class - 2022 (USD Billion)
  • 13. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class - 2022 (USD Billion)
  • 14. The Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class - 2022 (USD Billion)